| 영문 | therapy | 한글 | 요법 |
|---|---|---|---|
| 설명 | 병을 낫게 하는 것 또는 그 방법. |
||
| 영문 | gene therapy | 한글 | 유전자요법 |
|---|---|---|---|
| 설명 | 유전병을 치료할 목적으로, 정상적으로 기능하는 단일유전자 혹은 복수유전자를 어떤 기원에서 얻어내어 생세포에 도입하는 것. 유전물질은 유전자삽입 조작에 의해 수용세포에로 도입된다. 즉, 유전자를 끼워 넣은 새로운 세포를 사용하는 치료로서 1980년 미국의 학자가 지중해빈혈환자에게 강행하여 비판을 받았지만, 미국 국립보건연구소는 1990년 9월 아데노신 데아미나아제(adenosine deaminase, ADA) 결핍증 환자의 림프구에 ADA 유전자를 끼워 넣는 치료를 시작한 이래 현재는 암을 포함한 많은 질병들을 치료하는 목적으로 쓰인다. |
||
| 영문 | Electric convulsive therapy(ECT) | 한글 | 전기경련요법 |
|---|---|---|---|
| 설명 | 뇌에 전기 자극을 주어 인위적으로 경련을 유발함으로써 정신 병을 치료하는 방법. 전기쇼크요법(electroshock therapy)이라고도 한다. 1938년에 이탈리아의 체를레티와 비니에 의해 시작되었다. 작용기전은 확실치 않으나 뇌의 신진대사, 생화학 및 효소 등에 변화를 일으킨다는 생물학적, 생화학적 학설이 유력하다. 적응증으로 가장 효과적인 병은 우울증으로 특히 여성에서 갱년기에 호발하는 갱년기 우울증, 우울증과 조증(아주 기분이 좋은 상태가 지속되는 정신병)이 일정한 주기를 두고 반복하는 조울증에 잘 쓰이며, 80~90%에서 효과가 있다. |
||
| ICT | icteric, icterus; indirect Coombs test; inflammation of connective tissue; insulin coma therapy; int... |
|---|---|
| OT | objective test; oblique talus; occlusion time; occupational therapist, occupational therapy; ocular ... |
| MGG | May-Grunwald-Giemsa [staining]; molecular and general genetics; mouse gammaglobulin; multinucleated ... |
| HMW | High Molecular Weight |
| HMWM | High Molecular Weight Multimers |
| molecular pathology | The study of biochemical and biophysical cellular mechanisms as the basic factors in disease. (05 Mar 2000) |
|---|---|
| molecular probes | A group of atoms or molecules attached to other molecules or cellular structures and used in studying the properties of these molecules and structures. Radioactive DNA or RNA sequences are used in molecular genetics to detect the presence of a complementary sequence by molecular hybridization. (12 Dec 1998) |
| molecular probe techniques | The use of devices which use detector molecules to detect, investigate, or analyze other molecules, macromolecules, molecular aggregates, or organisms. (12 Dec 1998) |
| molecular sequence data | Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as genbank, european molecular biology laboratory (embl), national biomedical research foundation (nbrf), or other sequence repositories. (12 Dec 1998) |
| molecular sieve | A gel-like material with pore sizes of such ranges as to exclude molecules above certain sizes; used in fractionating or purifying macromolecules. (05 Mar 2000) |
| molecular structure | The location of the atoms, groups or ions relative to one another in a molecule, as well as the number and location of chemical bonds. (12 Dec 1998) |
| molecular weight | The sum of the atomic weight's of all the atoms constituting a molecule; the mass of a molecule relative to the mass of a standard atom, now 12C (taken as 12.000). Relative molecular mass (Mr) is the mass relative to the dalton and has no units. See: atomic weight. Synonym: molecular mass, molecular weight ratio, relative molecular mass. (05 Mar 2000) |
| molecular weight ratio | The sum of the atomic weight's of all the atoms constituting a molecule; the mass of a molecule relative to the mass of a standard atom, now 12C (taken as 12.000). Relative molecular mass (Mr) is the mass relative to the dalton and has no units. See: atomic weight. Synonym: molecular mass, molecular weight ratio, relative molecular mass. (05 Mar 2000) |
| heparin, low-molecular-weight | <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. Pharmacological action: anticoagulant, fibrinolytic agent. (12 Dec 1998) |
| directed molecular evolution | Techniques used to produce molecules exhibiting properties that conform to the demands of the experimenter. (12 Dec 1998) |
| epidemiology, molecular | The application of molecular biology to the answering of epidemiological questions. The examination of patterns of changes in DNA to implicate particular carcinogens and the use of molecular markers to predict which individuals are at highest risk for a disease are common examples. (12 Dec 1998) |
| european molecular biology lab gene bank | <molecular biology> A large database of DNA sequence data in Heidelberg, Germany, compiled from international sources. It is the European equivalent to the Genbank DNA sequence databank in the United States of America. WWW: EMbase. (09 Oct 1997) |
| evolution, molecular | Evolution at the molecular level of DNA sequences and proteins. (rieger et al., glossary of genetics: classical and molecular, 5th ed) (12 Dec 1998) |
| kinetic molecular theory | <chemistry> This theory assumes that molecules must collide in order to react. The more collisions the more likely it is for a reaction to occur. However, depending on the conditions, only a small fraction of the collisions are effective in producing a reaction. There are several constraints. In order for a reaction to occur, bonds initially are broken, which requires energy. This energy depends on the type of the reaction and comes from the kinetic energies that the molecules possess before the collision. It is called the activation energy. Increasing the temperature increases the kinetic energies and more collisions will occur. In adition, at a higher temperature a greater number of the reacting molecules might possess an energy equal to or greater than the activation energy. However the molecules must also collide in a specific orientation, called the steric factor in order for a reaction to occur. A reaction will only be successful, if the collision has enough energy to be either equal to or greater than the activation energy and if the orientation of the collision allows for correct bond formation. These factors are in the Arrhenius equation: k = zp The rate constant k is proportional to the Arrhenius factor A. A is the product of the collision frequency z, and the steric factor p. The fraction of collisions with sufficient energy to produce a reaction are in the term of the equation. (09 Jan 1998) |
| kininogen, high-molecular-weight | A plasma protein, molecular weight of 110 kD, that normally exists in plasma in a 1:1 complex with prekallikrein. Hmwk is split by plasma kallikrein to produce bradykinin. The complex is a cofactor in the activation of coagulation factor xii. The product of this reaction, xiia, in turn activates prekallikrein to kallikrein. (12 Dec 1998) |